AR025333A1 - Piperidinoalcoholes, un procedimiento para su preparacion, su empleo para preparar un medicamento, los medicamentos a base de estos compuestos y laspreparaciones farmaceuticas que los contienen. - Google Patents
Piperidinoalcoholes, un procedimiento para su preparacion, su empleo para preparar un medicamento, los medicamentos a base de estos compuestos y laspreparaciones farmaceuticas que los contienen.Info
- Publication number
- AR025333A1 AR025333A1 ARP000104296A ARP000104296A AR025333A1 AR 025333 A1 AR025333 A1 AR 025333A1 AR P000104296 A ARP000104296 A AR P000104296A AR P000104296 A ARP000104296 A AR P000104296A AR 025333 A1 AR025333 A1 AR 025333A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compounds
- indicated above
- disease
- hal
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 229940079593 drug Drugs 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 4
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 229910052794 bromium Inorganic materials 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 229910052740 iodine Inorganic materials 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 abstract 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 abstract 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 238000003747 Grignard reaction Methods 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 231100000867 compulsive behavior Toxicity 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000007327 hydrogenolysis reaction Methods 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical class ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 238000003797 solvolysis reaction Methods 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Piperidinoalcoholes de formula 1 en donde R1, R2 representa independientemente arilo o Het, arilo representa fenilo no sustituido o mono, di otrisustituido con Hal, CN, A, OA u OH, Het representa un sistema heterocíclico insaturado de uno o dos nucleos, que contiene uno, dos o tres heteroátomosiguales o diferentes tales como el nitrogeno, oxígeno y azufre, y que se encuentra no sustituido o mono, di o trisustituido con Hal, A, CN, OA u OH, Arepresenta alquilo C1-6, Hal representa F, Cl, Br, o I,y sus solvatos y sales aceptables desde el punto de vista fisiologico. Un procedimiento para prepararlos compuestos de formula 1, en el cual a)se hace reaccionar un compuesto de formula R1-CH2-CH2-L en donde representa Cl, Br, I o un grupo OH libreofuncionalmente transformado en un grupo reactivo, y R1 tiene el significado antes indicado con un componente de formula 2 en donde R2 y A tienen lossignificados antes indicados o b)mediante una reaccion de Grignard se hace reaccionar un compuesto de formula 3 en donde R1 y R2 tienen los significados antesindicados con un compuesto de formula R-X-A en donde R es yodo o bromo, X es Mg y A tiene el significado antes indicado o c)se lo libera de uno de susderivados funcionales por tratamiento conun agente de solvolisis o hidrogenolisis, o d) se transforma una base de formula 1, así obtenida, en una de sus salespor tratamiento con un ácido. Los compuestos de formula 1 y sus solvatos y sales aceptables desde el punto de vista fisiologico que constituyen medicamentosque actuan como antagonistas potentes del receptor 5-HT1A. Un medicamento a base de los compuestos de formula 1, que se destina al tratamiento de la psicosis,la esquizofrenia, la depresion, los trastornos neurologicos, los transtornos de la memoria, el Mal de Parkinson, la esclerosis lateral amiotrofica, laenfermedad de Alzheimer, la enfermedad de Huntington, los trastornos alimenticios tales como la bulimia, la anorexia nerviosa, el síndrome premestrual y/o aejercer una influencia positiva sobre los comportamientos obsesivos y compulsivos (OCD). Una composicion farmacéutica que contiene al menos un medicamento como
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19939756A DE19939756A1 (de) | 1999-08-21 | 1999-08-21 | Piperidinalkohole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR025333A1 true AR025333A1 (es) | 2002-11-20 |
Family
ID=7919197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104296A AR025333A1 (es) | 1999-08-21 | 2000-08-18 | Piperidinoalcoholes, un procedimiento para su preparacion, su empleo para preparar un medicamento, los medicamentos a base de estos compuestos y laspreparaciones farmaceuticas que los contienen. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6756370B1 (es) |
| EP (1) | EP1202966B1 (es) |
| JP (1) | JP2003507455A (es) |
| KR (1) | KR20020027502A (es) |
| CN (1) | CN1170819C (es) |
| AR (1) | AR025333A1 (es) |
| AT (1) | ATE268757T1 (es) |
| AU (1) | AU760392B2 (es) |
| BR (1) | BR0013467A (es) |
| CA (1) | CA2382295A1 (es) |
| CZ (1) | CZ2002499A3 (es) |
| DE (2) | DE19939756A1 (es) |
| DK (1) | DK1202966T3 (es) |
| ES (1) | ES2220537T3 (es) |
| HU (1) | HUP0203406A2 (es) |
| MX (1) | MXPA02001750A (es) |
| NO (1) | NO20020827D0 (es) |
| PL (1) | PL353590A1 (es) |
| PT (1) | PT1202966E (es) |
| SK (1) | SK2192002A3 (es) |
| WO (1) | WO2001014332A1 (es) |
| ZA (1) | ZA200202291B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US7902679B2 (en) * | 2001-03-05 | 2011-03-08 | Megica Corporation | Structure and manufacturing method of a chip scale package with low fabrication cost, fine pitch and high reliability solder bump |
| ATE460933T1 (de) * | 2002-05-24 | 2010-04-15 | Carl-Fr Coester | Pharmazeutische wirkstoffkombination sowie deren verwendung |
| BRPI0515860B8 (pt) * | 2004-12-21 | 2021-05-25 | Hoffmann La Roche | derivados de tetralin e indano, seus usos, e composição farmacêutica |
| CN101891672B (zh) * | 2010-07-07 | 2012-07-11 | 天津大学 | 哌啶酮加氢反应液提纯哌啶醇产品的分离提纯方法及装置 |
| US20120129834A1 (en) * | 2010-09-17 | 2012-05-24 | Buck Institute For Research On Aging | Serotonin receptor antagonists for use in the treatment of huntington's disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1280421C (en) * | 1985-07-02 | 1991-02-19 | Albert A. Carr | 1,4-disubstituted piperidinyl derivatives |
| US5093341A (en) * | 1987-12-17 | 1992-03-03 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine derivatives useful as antithrombolytic agents |
| WO1991018602A1 (en) * | 1990-06-01 | 1991-12-12 | Merrell Dow Pharmaceuticals Inc. | (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL |
| NZ249286A (en) * | 1992-02-13 | 1996-02-27 | Merrell Dow Pharma | Piperidine-4-ylmethyl thiophene and thiazole derivatives and pharmaceutical compositions |
| FR2696744B1 (fr) * | 1992-10-12 | 1994-12-30 | Logeais Labor Jacques | Dérivés de 2-pyrrolidone, leur procédé de préparation et leurs applications en thérapeutique. |
| AU1301497A (en) * | 1995-12-20 | 1997-07-14 | Reinhard Laven | Novel 1-phenylalkyl/alkylene-4-(.alpha.-hydroxydiphenylmethyl)-pip eridine derivatives and their use as serotonin antagonists |
| GB9718712D0 (en) * | 1997-09-03 | 1997-11-12 | Merck Sharp & Dohme | Theraputic Agents |
-
1999
- 1999-08-21 DE DE19939756A patent/DE19939756A1/de not_active Withdrawn
-
2000
- 2000-08-08 PT PT00964004T patent/PT1202966E/pt unknown
- 2000-08-08 PL PL00353590A patent/PL353590A1/xx unknown
- 2000-08-08 WO PCT/EP2000/007664 patent/WO2001014332A1/de active IP Right Grant
- 2000-08-08 CN CNB00811840XA patent/CN1170819C/zh not_active Expired - Fee Related
- 2000-08-08 DE DE50006759T patent/DE50006759D1/de not_active Expired - Fee Related
- 2000-08-08 CZ CZ2002499A patent/CZ2002499A3/cs unknown
- 2000-08-08 JP JP2001518422A patent/JP2003507455A/ja active Pending
- 2000-08-08 KR KR1020027000962A patent/KR20020027502A/ko not_active Application Discontinuation
- 2000-08-08 BR BR0013467-8A patent/BR0013467A/pt not_active IP Right Cessation
- 2000-08-08 SK SK219-2002A patent/SK2192002A3/sk unknown
- 2000-08-08 ES ES00964004T patent/ES2220537T3/es not_active Expired - Lifetime
- 2000-08-08 HU HU0203406A patent/HUP0203406A2/hu unknown
- 2000-08-08 MX MXPA02001750A patent/MXPA02001750A/es unknown
- 2000-08-08 AU AU75088/00A patent/AU760392B2/en not_active Ceased
- 2000-08-08 CA CA002382295A patent/CA2382295A1/en not_active Abandoned
- 2000-08-08 AT AT00964004T patent/ATE268757T1/de not_active IP Right Cessation
- 2000-08-08 US US10/069,054 patent/US6756370B1/en not_active Expired - Fee Related
- 2000-08-08 DK DK00964004T patent/DK1202966T3/da active
- 2000-08-08 EP EP00964004A patent/EP1202966B1/de not_active Expired - Lifetime
- 2000-08-18 AR ARP000104296A patent/AR025333A1/es not_active Application Discontinuation
-
2002
- 2002-02-20 NO NO20020827A patent/NO20020827D0/no not_active Application Discontinuation
- 2002-03-20 ZA ZA200202291A patent/ZA200202291B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ2002499A3 (cs) | 2002-05-15 |
| ATE268757T1 (de) | 2004-06-15 |
| DK1202966T3 (da) | 2004-09-27 |
| HUP0203406A2 (hu) | 2003-02-28 |
| CA2382295A1 (en) | 2001-03-01 |
| BR0013467A (pt) | 2002-04-30 |
| KR20020027502A (ko) | 2002-04-13 |
| DE50006759D1 (de) | 2004-07-15 |
| AU760392B2 (en) | 2003-05-15 |
| NO20020827L (no) | 2002-02-20 |
| ZA200202291B (en) | 2003-10-29 |
| PL353590A1 (en) | 2003-12-01 |
| CN1371365A (zh) | 2002-09-25 |
| PT1202966E (pt) | 2004-10-29 |
| CN1170819C (zh) | 2004-10-13 |
| JP2003507455A (ja) | 2003-02-25 |
| SK2192002A3 (en) | 2002-06-04 |
| ES2220537T3 (es) | 2004-12-16 |
| EP1202966B1 (de) | 2004-06-09 |
| DE19939756A1 (de) | 2001-02-22 |
| MXPA02001750A (es) | 2003-03-27 |
| AU7508800A (en) | 2001-03-19 |
| US6756370B1 (en) | 2004-06-29 |
| WO2001014332A1 (de) | 2001-03-01 |
| NO20020827D0 (no) | 2002-02-20 |
| EP1202966A1 (de) | 2002-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2774510T3 (es) | Derivados de 1,3,4-oxadiazol sulfamida como inhibidores de histona desacetilasa 6 y composición farmacéutica que comprende los mismos | |
| JP6621329B2 (ja) | 新規化合物、それらの合成及びそれらの使用 | |
| AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| ATE107922T1 (de) | 2-(1-piperazinyl)-4-phenylcycloalkanpyridin- derivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die sie enthalten. | |
| AR050952A1 (es) | Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1. | |
| EP3366688A1 (en) | Substituted pyrazolopyrimidines as glucocerebrosidase activators | |
| PE20091444A1 (es) | Derivados de isoxazolo-pirazina | |
| CN101677563A (zh) | 5,6-二氢-1h-吡啶-2-酮化合物 | |
| MA30315B1 (fr) | Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| AR067412A1 (es) | Moduladores de propiedades farmaceuticas de productos terapeuticos | |
| HUT48589A (en) | Process for production of new derivatives of substituated n-/1-hydroxi-4-piperidinil/-benzamid | |
| CN101970399A (zh) | 组蛋白脱乙酰酶抑制剂 | |
| AR025333A1 (es) | Piperidinoalcoholes, un procedimiento para su preparacion, su empleo para preparar un medicamento, los medicamentos a base de estos compuestos y laspreparaciones farmaceuticas que los contienen. | |
| CN104703985A (zh) | 作为pi3-激酶信号通路调节剂的芳基和杂芳基取代的苯衍生物 | |
| BR9812239A (pt) | Composto, formulação farmacêutica, uso do composto, processos para o tratamento de distúrbios, para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e, para a preparação do composto | |
| US20160257657A1 (en) | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | |
| AR043510A1 (es) | Derivados de quinolinona, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden | |
| AR024818A1 (es) | Derivados de la n-(indolcarbonil)-piperazina, un procedimiento para su preparacion, su empleo para preparar un medicamento, los medicamentos a base de losmismos y las preparaciones farmaceuticas que los contienen. | |
| RU2002103301A (ru) | Производные индола | |
| KR880001593A (ko) | 4-(아로일아미노)피페리딘부탄아미드 유도체 | |
| ES2465005T3 (es) | Derivado de óxido de benzotiofeno y sus sales | |
| US10654805B2 (en) | Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease | |
| JP7144863B2 (ja) | イソキノリン化合物、その調製の方法、およびベータガラクトシダーゼの活性の変質に伴う状態におけるその治療的使用 | |
| AR035682A1 (es) | Piperazinilcarbonilquinolinas e -isoquinolinas, un proceso para su preparacion, las preparaciones farmaceuticas que las contienen, el uso de las mismas para preparar un medicamento, los antagonistas selectivos del receptor de 5-ht2a que conforman estos compuestos y el uso de estos antagonistas en la | |
| ATE215080T1 (de) | 1,2-dithiolan derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |